Methods of treating iga nephropathy with atrasentan

MYPI2026001667A0Undetermined Publication Date: 2021-06-17CHINOOK THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026001667
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-16
Filing Date
2020-12-16
Publication Date
2021-06-17
Patent Text Reader

Abstract

Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and / or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV / AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.
Need to check novelty before this filing date? Find Prior Art